GlobeNewswire: IN8bio, Inc Contains the last 10 of 129 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:06:22ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/14/2846670/0/en/IN8bio-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Recent-Business-Highlights.html?f=22&fvtc=4&fvtv=51225IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights2024-03-14T20:00:00Z<![CDATA[NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/03/05/2840932/0/en/IN8bio-to-Present-New-Preclinical-Data-on-Novel-Gamma-Delta-CAR-Platform-Candidate-at-AACR-Annual-Meeting-2024.html?f=22&fvtc=4&fvtv=51225IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 20242024-03-05T21:30:00Z<![CDATA[NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell (CAR-T) platform, INB-300. The data will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California.]]>https://www.globenewswire.com/news-release/2024/02/14/2829025/0/en/IN8bio-Announces-Publication-on-Novel-Gamma-Delta-T-Cell-Therapy-for-Glioblastoma-in-Frontiers-in-Immunology.html?f=22&fvtc=4&fvtv=51225IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology2024-02-14T13:00:00Z<![CDATA[Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy]]>https://www.globenewswire.com/news-release/2024/01/04/2803970/0/en/IN8bio-Highlights-Recent-Company-Accomplishments-and-Outlines-2024-Pipeline-Goals.html?f=22&fvtc=4&fvtv=51225IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals2024-01-04T13:00:00Z<![CDATA[NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent business updates and provided pipeline goals for 2024.]]>https://www.globenewswire.com/news-release/2023/12/11/2794257/0/en/IN8bio-Announces-Positive-Clinical-Update-Demonstrating-Continued-Durable-Complete-Remission-in-100-of-Evaluable-Patients-in-Phase-1-Trial-of-INB-100-in-Leukemia.html?f=22&fvtc=4&fvtv=51225IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia2023-12-11T21:05:00Z<![CDATA[NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced positive updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies. The data, which will be presented in a poster presentation at the 65th ASH Annual Meeting & Exposition this evening, demonstrated that 100% of evaluable leukemia patients (n=10) treated remained alive, progression-free, and in durable complete remission (CR) as of November 3, 2023. The Company believes this data indicate the curative potential of INB-100 to provide durable relapse free periods for high-risk or relapsed AML and other hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). The CRs to date, combined with INB-100’s benefit/risk profile are encouraging for the treatment of hematological malignancies and the trial is being expanded by ten patients at Dose Level (DL) 2, the recommended Phase 2 dose (RP2D). Additional expansion patient enrollment is on-going and updated data is expected to be presented at medical meetings in 2024.]]>https://www.globenewswire.com/news-release/2023/12/11/2793919/0/en/IN8bio-Announces-Pricing-of-Financing-Totaling-up-to-46-9-Million-in-Private-Placement.html?f=22&fvtc=4&fvtv=51225IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement2023-12-11T14:00:47Z<![CDATA[Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations]]>https://www.globenewswire.com/news-release/2023/12/07/2792463/0/en/IN8bio-Appoints-Dr-Corinne-Epperly-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=51225IN8bio Appoints Dr. Corinne Epperly to Board of Directors2023-12-07T13:00:00Z<![CDATA[NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors.]]>https://www.globenewswire.com/news-release/2023/12/05/2790866/0/en/IN8bio-to-Host-Investor-Call-at-8-30-AM-ET-on-Tuesday-December-12-to-Discuss-Updated-Clinical-Data-from-Phase-1-Trial-of-INB-100-in-Patients-with-Leukemia.html?f=22&fvtc=4&fvtv=51225IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia2023-12-05T13:00:00Z<![CDATA[NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the Company will host a conference call on Tuesday, December 12, 2023 at 8:30 am ET. The event will highlight data presented at the ASH 65th Annual Meeting in a poster presentation on December 11, 2023 starting at 6:00 pm PT. The Company’s INB-100 trial is focused on investigating the potential of harnessing donor-derived allogeneic gamma-delta T cells for the treatment of patients with hematological malignancies following hematopoietic bone marrow transplantation (HSCT).]]>https://www.globenewswire.com/news-release/2023/11/20/2783105/0/en/IN8bio-s-INB-200-Demonstrates-Extended-Progression-Free-Survival-in-Patients-with-Newly-Diagnosed-Glioblastoma.html?f=22&fvtc=4&fvtv=51225IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma2023-11-20T12:00:00Z<![CDATA[All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months]]>https://www.globenewswire.com/news-release/2023/11/10/2778199/0/en/IN8bio-to-Present-Data-Highlighting-Potential-of-INB-200-and-INB-400-to-Treat-Patients-with-Newly-Diagnosed-Glioblastoma-Multiforme-at-Society-for-Neuro-Oncology-28th-Annual-Meetin.html?f=22&fvtc=4&fvtv=51225IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting2023-11-10T12:00:00Z<![CDATA[Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200]]>